These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7057187)

  • 1. On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain.
    Westerink BH; Spaan SJ
    J Neurochem; 1982 Mar; 38(3):680-6. PubMed ID: 7057187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of dopamine metabolites in the evaluation of drugs acting on dopaminergic neurons.
    Di Giulio AM; Groppetti A; Cattabeni F; Galli CL; Maggi A; Algeri S; Ponzio F
    Eur J Pharmacol; 1978 Nov; 52(2):201-7. PubMed ID: 729633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial 3-methoxytyramine reflects striatal dopamine release: an in vivo microdialysis study.
    Brown EE; Damsma G; Cumming P; Fibiger HC
    J Neurochem; 1991 Aug; 57(2):701-7. PubMed ID: 1906527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of yohimbine in blocking rat central dopamine autoreceptors in vivo.
    van Oene JC; de Vries JB; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Oct; 327(4):304-11. PubMed ID: 6514014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain.
    Westerink BH; Kikkert RJ
    J Neurochem; 1986 Apr; 46(4):1145-52. PubMed ID: 3950621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study.
    Butcher SP; Fairbrother IS; Kelly JS; Arbuthnott GW
    J Neurochem; 1988 Feb; 50(2):346-55. PubMed ID: 2447237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain.
    Karoum F; Chrapusta SJ; Brinjak R; Hitri A; Wyatt RJ
    Br J Pharmacol; 1994 Dec; 113(4):1391-9. PubMed ID: 7889297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum.
    Nissbrandt H; Sundström E; Jonsson G; Hjorth S; Carlsson A
    J Neurochem; 1989 Apr; 52(4):1170-82. PubMed ID: 2564423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of certain dopaminergic drugs on the striatal concentration of dopamine metabolites, with special reference to 3-methoxytramine.
    Ponzio F; Achilli G; Perego C; Algeri S
    Neurosci Lett; 1981 Nov; 27(1):61-7. PubMed ID: 7329624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dopamine metabolite 3-methoxytyramine is not a suitable indicator of dopamine release in the rat brain.
    Vulto AG; Westenberg HG; Meijer LB; Versteeg DH
    J Neurochem; 1986 Nov; 47(5):1387-93. PubMed ID: 3760867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of haloperidol and gamma-butyrolactone with (+)-amphetamine-induced changes in monoamine synthesis and metabolism in rat brain.
    Kehr W; Speckenbach W; Zimmermann R
    J Neural Transm; 1977; 40(2):129-47. PubMed ID: 323421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some factors affecting striatal 3-methoxytyramine concentrations in the mouse and rat.
    McQuade PS; Richard JW; Thakur M
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):725-9. PubMed ID: 4089199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haloperidol and clozapine increase intraneuronal dopamine metabolism, but not gamma-butyrolactone-resistant dopamine release.
    Chrapusta SJ; Karoum F; Egan MF; Wyatt RJ
    Eur J Pharmacol; 1993 Mar; 233(1):135-42. PubMed ID: 8472742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detection. Studies with drugs which alter dopamine metabolism in the brain.
    Heal DJ; Frankland AT; Buckett WR
    Neuropharmacology; 1990 Dec; 29(12):1141-50. PubMed ID: 2293058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of drugs interfering with dopamine and noradrenaline biosynthesis on the endogenous 3,4-dihydroxyphenylalanine levels in rat brain.
    Westerink BH; van Es TP; Spaan SJ
    J Neurochem; 1982 Jul; 39(1):44-51. PubMed ID: 6123552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of phencyclidine on dopamine synthesis and metabolic in rat striatum.
    Doherty JD; Simonovic M; So R; Meltzer HY
    Eur J Pharmacol; 1980 Jul; 65(2-3):139-49. PubMed ID: 7398783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-Methoxytyramine as an indicator of impulse-induced dopamine release in rat brain in vivo.
    Kehr W
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Jun; 293(3):209-15. PubMed ID: 958511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model.
    Karoum F; Chrapusta SJ; Egan MF
    J Neurochem; 1994 Sep; 63(3):972-9. PubMed ID: 7914228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebral dialysis: direct evidence for the utility of 3-MT measurements as an index of dopamine release.
    Wood PL; Kim HS; Marien MR
    Life Sci; 1987 Jul; 41(1):1-5. PubMed ID: 3600173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-Methoxytyramine accumulation: effects of typical neuroleptics and various atypical compounds.
    Saller CF; Salama AI
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Oct; 334(2):125-32. PubMed ID: 2878374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.